Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Strange

Showing results (191-200 of 200) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 200 results.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
The New England Journal of Medicine|March 18, 2011
Efficacy and safety of sirolimus in lymphangioleiomyomatosisFrancis X McCormack, Yoshikazu Inoue, Joel Moss, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The European Respiratory Journal|September 18, 2025
Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiencyJ Michael Wells, Ingrid L Titlestad, Hanan Tanash, et al.
Annals of the American Thoracic Society|March 11, 2025
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin Deficient Individuals with Tobacco Smoking History from the SPIROMICS CohortIgor Barjaktarevic, Roxana Hixson, Zian Zhuang, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|March 24, 2025
The Use of CT Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner SocietyRaúl San José Estépar, R Graham Barr, Sean B Fain, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2016
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and ManagementFrancis X McCormack, Nishant Gupta, Geraldine R Finlay, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|October 6, 2020
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)Chunxue Bai, Sanjay H Chotirmall, Jordi Rello, et al.
Pageof 20

Showing results (191-200 of 200) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 200 results.
The New England Journal of Medicine|June 23, 2006
Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
The New England Journal of Medicine|March 18, 2011
Efficacy and safety of sirolimus in lymphangioleiomyomatosisFrancis X McCormack, Yoshikazu Inoue, Joel Moss, et al.
Arthritis and Rheumatism|May 1, 2007
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna, Xiaohong Yan, Donald P Tashkin, et al.
The European Respiratory Journal|September 18, 2025
Two randomised controlled phase 2 studies of the oral neutrophil elastase inhibitor alvelestat in alpha-1 antitrypsin deficiencyJ Michael Wells, Ingrid L Titlestad, Hanan Tanash, et al.
Annals of the American Thoracic Society|March 11, 2025
Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin Deficient Individuals with Tobacco Smoking History from the SPIROMICS CohortIgor Barjaktarevic, Roxana Hixson, Zian Zhuang, et al.
American Journal of Respiratory and Critical Care Medicine|August 25, 2007
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin, Robert Elashoff, Philip J Clements, et al.
American Journal of Respiratory and Critical Care Medicine|March 24, 2025
The Use of CT Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner SocietyRaúl San José Estépar, R Graham Barr, Sean B Fain, et al.
American Journal of Respiratory and Critical Care Medicine|September 16, 2016
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and ManagementFrancis X McCormack, Nishant Gupta, Geraldine R Finlay, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|October 6, 2020
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)Chunxue Bai, Sanjay H Chotirmall, Jordi Rello, et al.
Pageof 20